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Objective. The aim of this study is to look at possible diﬀerences in outcome between serosa and adnexal involvement stage IIIA
endometrial carcinoma. Methods. 67 patients with stage IIIA endometrial carcinoma were included, 46 with adnexal involvement
and 21 with serosa. A central histopathological review was performed. Results. The 7-year locoregional failure rate was (LRFR)
2.2% for adnexal involvement and 16.0% for involvement of the serosa (P = .0522). The 7-year distant metastasis-free survival
was 72.7% for adnexal involvement and 58.7% for serosa (P = .3994). The 7-year disease-speciﬁc survival (DSS) was 71.8%
for patients with adnexal involvement and 75.4% for patients with serosa. Conclusion. Endometrial carcinoma stage IIIA with
involvement of the adnexa or serosa showed to have a comparable disease-speciﬁc survival. Locoregional control was worse for
serosa involvement compared to adnexa.
1.Introduction
The majority of patients with endometrial cancer are
diagnosed without evidence of extra uterine spread, leading
to only 10–15% of the patients with stage III disease [1].
In 1988, the International Federation of Gynecology and
Obstetrics (FIGO) mandated the staging of endometrial
cancer be changed from a clinical staging system to a surgical
staging system because of the inaccuracies of the former.
Staging of the disease is since then based on pathological
criteria after initial resection and evaluation.
According to FIGO 1997 stage IIIA endometrial car-
cinoma is deﬁned as tumor involvement either as direct
extension ormetastasis toserosa, parametria, adnexa, and/or
cancer cells in peritoneal washings [2]. Due to this broad
deﬁnition, patients with stage IIIA form a heterogeneous
group. Diﬀerent types of tumor involvement within this
heterogeneous group might have impact on prognostic
factors and outcome. Due to the heterogeneity of the tumor
characteristics in this stage and the low incidence only small
series have been published. FIGO has recently updated the
staging system with a signiﬁcant change to the staging of2 Obstetrics and Gynecology International
endometrial carcinoma stageIIIA. The presence ofabnormal
cells in peritoneal washings no longer aﬀects staging. This
resulted in a less heterogeneous stage IIIA.
We had the opportunity to do a multi-institutional study
on stage IIIA with isolated involvement of the serosa and
adnexa. The aim of this study is to reveal possible diﬀerences
in outcomebetween isolated serosa and adnexal involvement
and determine possible prognostic factors in two homo-
geneous groups of patients with stage IIIA endometrial
carcinoma based solely on involvement of the adnexa or the
serosa.
2.PatientsandMethods
All patients with FIGO stage IIIA, according to the 1997 and
2008 FIGO staging, endometrial carcinoma endometrioid
type, based on isolated adnexa or serosal involvement were
identiﬁed in six radiotherapy departments in the Nether-
lands over the period 1987 through 2005. All institutes had
the opportunity to send in patients covering the above-
mentioned period, which resulted in a total of 93 patients.
The clinical data of the patients were collected from
the charts: age at diagnosis, surgical procedure, histology,
grade, depth of myometrium invasion, lymph vascular space
involvement(LVSI),cervicalinvolvement,positiveperitoneal
washing, adjuvant radiotherapy features, follow-up data
(date and site of recurrence), and vital status.
A central histopathology review of all 93 patients was
performed at the Laboratory of Pathology Oost Nederland
by a single pathologist. All pathologicsections were reviewed
on histology, grade, depth of myometrium invasion, LVSI,
extent of cervical involvement, and extension of the tumor
outside the uterus.
The presence of a positive peritoneal washing was not
routinely looked at and primarily not used as a variable for
staging, but as an independent variable in the analysis.
Patients included in this study had only isolated involve-
ment of the adnexa or the serosa. Patients with multiple
involved sites were excluded.Involvement of both serosa and
adnexawasalsoanexclusioncriterion,leaving67patientsfor
analysis after pathological review.
2.1. Treatment. All patients were primarily operated on.
Standard surgery for clinical stage I endometrial carcinoma
was total abdominal hysterectomy and bilateral salpingo-
ooforectomie (TAH + BSO). In case of a suspected clinical
stage II, the surgery was TAH + BSO and staging lym-
phadenectomy or Wertheim radical hysterectomy. Sixty-
threepatients(94%)hadTAH+BSO,twopatientunderwent
TAH with staging procedure, one patient had a vaginal hys-
terectomy, and one patient had a supracervical hysterectomy.
Preoperativeimagingtoidentifyoccultmetastaticdisease
was not standard. Pathological stage IIIA endometrial carci-
noma after TAH + BSO was a generally accepted indication
in The Netherlands for postoperative external radiotherapy
with or without vaginal vault irradiation, depending on the
extension of the tumor and/or the radiotherapy department
policy.
Nearly all patients, 95.5%(64/67),receivedpostoperative
pelvic external radiotherapy. The target volume included the
upper two third of the vagina and the regional nodes. The
upper border was deﬁned at the L5-S1 interspace; the caudal
borderwas deﬁned to be theinferior margin of theobturator
foramen. The lateral borders included the widest opening
of the bony pelvis with a 1.5cm margin. The external dose
ranged from 30.0 to 46.0Gy in 1.8–2.3Gy fractions 4-5
times a week. Of the 64 patients, the majority (82.8%)
received 46.0Gy in 2.0Gy fractions 5 times a week. From
the64patientswithpostoperativepelvicradiotherapy,25.0%
(16/64)receivedaboosttothevaginalvaultbybrachytherapy
and7.8%(5/64)byexternalradiotherapy.Thebrachytherapy
was fourteen times an application by vaginal cylinder and
two times by ovoid’s. The external boost was twice 20.0Gy
and three times 14.0Gy, all in 2.0Gy fractions.
Three patients from one center received total abdominal
external radiotherapy of 20.0Gy in 1.0Gy fractions followed
by a boost to the pelvic with doses of 20.0–24.0Gy in
2.0Gy fractions. Two of the three also received a boost by
brachytherapy through vaginal cylinder.
No adjuvant systemic therapy was given.
2.2. Statistical Methods. Time to recurrence and last date
of followup were calculated from the time of surgery. To
test for between-group diﬀerences for categorical data, Chi-
square tests were used. The locoregional failure rate (LRFR)
is deﬁned as the number of vaginal and/or pelvic recur-
rences. Distant metastases were regarded as all extra pelvic
recurrences, for example, abdomen, para-aortal, liver, lung,
and bone. The distant metastasis-free survival (DMFS) was
deﬁned as survival without distant metastasis. The endpoint
for the survival analysis was disease-speciﬁc survival (DSS),
with censoring at date of the last contact or death due to
other causes than endometrial carcinoma. Survival statistics
were calculated by the method of Kaplan and Meier. For
comparison of survival distributions the log-rank test was
used. In univariate analysis we used the following variables:
age, type of surgery, grade of diﬀerentiation, degree of cer-
vical involvement, presence of positive peritoneal washing,
presence oflymph vascular space involvement(LVSI),degree
of myometrium involvement, type of adjuvant radiotherapy,
use of adjuvant brachytherapy, and total external radiation
dose.Variables thatwere univariately related tothe outcomes
of interest (P<. 05) were entered in a multivariate Cox
regression analysis.
The primary analyses were conductedwith all 67 patients
comparing adnexa and serosal involvement. A secondary
analysis was performed with adnexa and serosal involvement
separately.
Allanalysesarebasedonthehistopathologicallyreviewed
data.
All analyses were performed using STATA [3].
3.Results
The tumor and treatment characteristics of all67 patients,46
with involvement of adnexa and 21 with serosa, are shown inObstetrics and Gynecology International 3
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Figure 1: Distant metastasis-free survival for endometrial carci-
noma stage IIIA according to involvement of the adnexa or serosa
(log rank P = .3994).
Table 1. Age ranged from 40 to 87 years for all 67 patients
with a median of 67 years. The median age for patients with
involvementof theadnexa was signiﬁcantly youngerthan the
age of patients with involvement of the serosa (63.5 versus
71-years, resp.). The followup ranged from 3 to 217 months
with a median of 56 months.
3.1. Locoregional Recurrence. The incidence during followup
of locoregional recurrence was 2.2% (1/46) for patients with
adnexal involvement and 14.3% (3/21) for patients with
serosal involvement, which was not signiﬁcantly diﬀerent
(P = .13). The 2-, 5-, and 7-year LRFR was 2.2% for adnexal
involvement, and 10.0%, 16.0%, and 16.0% for involvement
of the serosa, respectively. The log-rank test for equality
of survival functions was signiﬁcant for involvement of the
cervix (P = .0098) and borderline signiﬁcant (P = .0522)
comparing adnexa and serosal involvement.
In a separate univariate analysis for patients with
involvement of the serosa, only involvement of the cervix
(P = .004) was signiﬁcantly related to locoregional failure.
None of the patients without cervical involvement showed
locoregional failure. One patient with endocervical glands
involvement and two patients with stroma involvement
showed locoregional failure.
3.2. Distant Metastasis. The incidence of distant metastasis
was 26.1% (12/46) for patients with adnexal involvement
and 33.3% (7/21) for patients with involvement of the serosa
(P = .54). The 2-, 5-, and 7-year DMFS was 84.3%, 76.4%,
and 72.7% for adnexal involvement and 83.6%, 58.7%, and
58.7% for serosal involvement, respectively (Figure 1).
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Figure 2: Distant metastasis-free survival for endometrial carci-
noma stage IIIA with involvement of the adnexa according to
presence oflymph vascularspace involvement(logrankP = .0002).
In univariate analysis for all patients presence of LVSI
(P<. 001) and myometrium inﬁltration of >50% (P = .011)
were signiﬁcantly related to DMFS. Involvement of adnexa
versus serosa was not signiﬁcant (P = .40). In a multivariate
analysisonlythepresenceofLVSI(HR3.1;95%CI1.03–9.11;
P = .043) was signiﬁcant.
Separate analysis for patients with adnexal involvement
showed grade of diﬀerentiation (P = .019), LVSI (P<. 001),
degree of myometrium inﬁltration (P = .012), and type of
postoperative radiotherapy (P = .041) to be signiﬁcantly
related to DMFS. Due to small numbers, multivariate
analysis was not reliable.
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with involvement of the adnexa was 42.6% versus 90.6%
(Figure 2).
Analysis for patients with involvement of the serosa
showed that none of the variables were signiﬁcantly related
to DMFS.
3.3. Disease-Free Survival. The 2-, 5-, and 7-year disease-free
survival (DFS) was 84.3%, 76.4%, and 76.4% for patients
with adnexal involvement and 84.3%, 59.6%, and 59.6%
for patients with serosal involvement. Of the patients with
adnexal involvement 12 showed distant metastasis, and one
of those also showed a pelvic recurrence. Of those with
serosal involvement7showed distantmetastasis, andofthose
3 patients also showed a vaginal recurrence.
Inunivariate analysis for allpatients onlyLVSI(P<. 001)
and myometrium involvement (P = .015) were signiﬁcantly
related to DFS. Grade of diﬀerentiation showed borderline4 Obstetrics and Gynecology International
Table 1: Tumor and treatment characteristics of 67 patients with endometrial carcinoma stage IIIA according to adnexa or serosa
involvement.
Characteristics Adnexa Serosa P value
n = 46 (%) n = 21 (%)
Age
<60 years 21 (45.7) 4 (19.1)
≥60 years 25 (54.3) 17 (80.9) .037
Diﬀerentiation grade
Grade 1 23 (50) 7 (33.3)
Grade 2 11 (23.9) 8 (38.1) Ns
Grade 3 12 (26.1) 6 (28.6)
Lymph vascular space involvement
yes 19 (41.3) 9 (42.9)
none 27 (58.7) 12 (57.1) Ns
Myometrium inﬁltration
<1/2 21 (43.5) 0 (0)
>1/2 26 (56.5) 20 (100)
Cervical involvement
none 29 (63) 13 (61.9)
endocervical glands 2 (4.4) 1 (4.8) Ns
stroma 15 (32.6) 7 (33.3)
Peritoneal washing
Positive 7 (15.2) 1 (4.8)
Negative 15 (32.6) 8 (38.1) Ns
Unknown 24 (52.2) 12 (57.1)
Type of radiotherapy
Pelvic 26 (56.5) 18 (85.7)
Pelvic + brachytherapy 13 (28.3) 2 (9.5) Ns
Pelvic + external boost 4 (8.7) 1 (4.8)
Abdomen/pelvic 1 (2.2) 0
Abd/pelvic + brachy 2 (4.4) 0
External dose (no boost)
30.0Gy 1 (2.2) 0
36–45.0Gy 11 (23.9) 2 (9.5) Ns
46.0Gy 34 (73.9) 19 (90.5)
signiﬁcance (P = .056). Involvement of adnexa or serosa did
not show signiﬁcant relationship with DFS. In multivariate
analysis only presence of LVSI (HR 3.6; 95% CI 1.07–12.0;
P = .038) was signiﬁcant.
From the 46 patients with involvement of the adnexa
11 (23.9%) developed recurrences, of which one patient
showed both locoregional and distant metastasis. Separate
univariate analyses in patients with involvement of adnexa
showed grade of diﬀerentiation (P = .009), LVSI (P<. 001),
myometrium inﬁltration (P = .019), and type of postoper-
ative radiotherapy (P = .026) to be signiﬁcantly related to
DFS. Due to small numbers, multivariate analysis was not
reliable.
Of the 21 patients with involvement of the serosa seven
patients (33.3%) showed recurrences, of which three showed
both locoregional and distant metastasis. In a univariate
analysis only cervicalinvolvementwas signiﬁcantly related to
DFS (P = .012).
3.4. Disease-Speciﬁc Survival. The 2-, 5-, and 7-year DSS
was 91%, 76.3%, and 71.8% for patients with adnexal
involvement and 100%, 75.4%, and 75.4% for patients with
serosal involvement (Figure 3).
In a univariate analysis for all patients grade of diﬀer-
entiation (P = .0091), peritoneal washings (P = .038),
and myometrium inﬁltration (P = .043) were signiﬁcantly
relatedtoDSS.Inamultivariateanalysisincludingtheabove-
mentioned variables only grade showed signiﬁcance. Grade
3 had higher risk of death due to the cancer compared to
grade 1 (HR 9.5; 95% CI 1.70–53.35; P = .010) and grade 2
compared to grade 1 (HR 6.2; 95% CI 1.18–33.14;P = .031).
Separate univariate analyses for patients with involve-
ment of the adnexa showed grade of diﬀerentiation (P =
.004), peritoneal washings (P = .024), LVSI (P = 0.001),
myometrium inﬁltration (P = .021), and type of postopera-
tive radiotherapy (P = .047) to be signiﬁcant. Due to small
numbers, multivariate analysis was not reliable.Obstetrics and Gynecology International 5
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Figure 3: Disease-speciﬁc survivalforendometrialcarcinomastage
IIIA according to involvement of the adnexa or serosa (log rank
P = .9194).
In a univariate analysis for patients with involvement of
the serosa none of the variables showed signiﬁcance.
4.Discussion
Our study showed that patients with stage IIIA endometrial
carcinoma with involvement of adnexa or the serosa had
comparabledisease-speciﬁc survival of71.8%and 75.4%at7
years, respectively. DMFS and DFS showed that patients with
involvement of the serosa had a slightly worse outcome, but
this diﬀerence was not signiﬁcant. Locoregional control was
excellent for patients with involvement of the adnexa, being
only in 2.2% of the patient’s recurrences, but was worse for
patients with serosal involvement (14.3% recurrences).
The management and outcome for patients with stage
IIIA endometrial cancer in the literature are diverse and
unclear, due to the heterogeneity ofthe tumorcharacteristics
in this stage and the low incidence leading to overall
small series. Since several reports have shown that positive
peritoneal cytology is not an independent prognostic factor
if endometrial canceris limitedto theuterus,this item in this
study is not regarded as a stage IIIA factor [4, 5]. This is in
accordance with the new FIGO staging. Positive peritoneal
washing is used as a variable comparable to myometrium
involvement in the analysis.
In 2006 Randall published the results of a phase III trial
comparing whole-abdominal irradiation versus chemother-
apy for stage III and IV endometrial carcinoma [6]. They
looked at stage III, incorporating IIIA, B, and C, and also
used whole-abdominal irradiation. The heterogeneity of
stage III and the diﬀerent irradiation make it diﬃcult to
c o m p a r eo u rr e s u l t sw i t ht h i st r i a l .
Inourmulti-institutional study we were able tocomprise
a relative large homogeneous group of patients with isolated
involvement of the adnexa and also a group with only
involvement of the serosa. To overcome the disadvantage
of multi-institutional, a central pathological review by one
pathologist was performed. Also the primary treatment
being surgery and adjuvant radiotherapy was fairly homo-
geneous.
Most studies looking at prognostic factors for patients
with stage IIIA endometrial carcinoma with involvement of
the adnexa and/or serosa include also patients with other
extra uterine spread, which makes it hard to compare our
results with the literature [7–13].
Only few have lookedat possible predictiveor prognostic
factors in these subgroups of stage IIIA [10]. This is of
course due to the low incidence. As we know from the
FIGO classiﬁcation and have seen in our previous study,
stage IIIA endometrial carcinoma is a heterogeneous group
of patients [14]. We showed in our previous study that the
number of involved sites is a strong negative prognostic
factor. The majority show involvement of the adnexa alone
or in association with other sites outside the uterus.
Severalstudiesshowed patientswithextrauterinedisease
limited to the adnexa to have 5-year DFS ranging from 71 to
86% [12, 13, 15–18]. Preyer et al. in a retrospective study of
36 patients with adnexal involvement only and 10 patients
with serosal involvement only found a median survival for
both of 56.7 and 115.8 months, respectively [8].
Connell et al. found a 70.9% 5-year DFS for patients
with solitary adnexal involvement with twenty patients [10].
He concluded that the relatively poor outcome seen in
these patients is the result of known risk factors including
diﬀerentiation grade, LVSI, and presence of additional sites
of extra uterine disease.
The DFS and DSS rates found in our study were
comparable to rates reported previously.
In contrast to most studies we had a relatively large
group of patients with only adnexa or serosal involvement,
making it possible to look at possible prognostic factors.
In our separate analysis of 46 patients with involvement
of the adnexa only, we were able to show in multivariate
analysis LVSI and myometrium inﬁltration of the tumor to
be independent prognostic factors, although we have to be
aware of the small numbers resulting in large conﬁdence
intervals. Recurrences outside the pelvic area were the main
problem for those patients. We had only one locoregional
recurrence compared to 12 outside the pelvic area. Whether
this excellent locoregional control is due to the treatment
or surgery plus radiotherapy or inherent to the tumor
characteristics cannotbeanswered inthisstudy.Ontheother
hand looking at the rate of recurrences outside the pelvis,
adjuvant systemic therapy should be considered for those
patients. These results also questionthe necessity of adjuvant
radiotherapy for patients with solitary adnexal involvement
and no presence of LVSI or myometrium inﬁltration <50%.
Although the numbers are small, the diﬀerences in DMFS
and DSS are highly signiﬁcant. Randomized studies regard-
ing treatment for these patients are not possible taking6 Obstetrics and Gynecology International
into account the low incidence. Further retrospective or
prospective studies might answer this question.
Mariani et al. in a retrospective study of 14 patients with
adnexaorserosal involvementorbothobserveda57%5-year
DFS [7]. From those 14 patients 6 had serosal involvement.
The 5-year DFS with serosal involvement compared to
none was 17% and 87.5%, respectively. In a retrospective
analysis of 19 patients with endometrial carcinoma stage
IIIA Ashman et al. looked at outcome and prognostic factors
[13]. Fifteen of those had solitary serosal involvement and
showeda41.5%5-yearDFS.Sevenofthosedevelopeddistant
recurrences, and only one pelvic recurrence was seen. In
our analysis of 21 patients with involvement of the serosa
only we had a 59.6% DFS, but we were not able to distillate
any prognostic factor in multivariate and univariate analysis.
Recurrences outside the pelvic area (33.3%) were the main
problem compared to 14.3% pelvic recurrences.
Patients with adnexa or serosal involvement have been
shown to beneﬁt from radiation therapy for locoregional
control [19]. For patients with isolated serosal involvement;
there is a decreased rate of pelvic recurrences with radiother-
apy [13].
In this study recurrences were mainly outside the
pelvis.Eighteen(26.9%)patientsshowedrecurrencesoutside
the pelvis, and from those 18 patients four also had a
locoregional recurrence. From the point of locoregional
control one can argue that postoperative radiotherapy to
the pelvis results in a good locoregional control, which
is consistent with others. Only this does not prove that
adjuvant radiotherapy should be the treatment of choice.
Looking at the results of this study and if we are able to
minimize thesideeﬀectsofpostoperativeradiotherapytothe
pelvic, this would be a pro- to postoperative radiotherapy
for stage IIIA endometrial carcinoma with isolated adnexa
or serosal involvement and should be considered part of
the standard treatment. Long-term followup of endometrial
carcinomapatientstreatedwith adjuvantpelvicradiotherapy
in the PORTEC I study shows us relatively high rates
of late morbidity (grade 1) [20]. On the other hand the
current study also shows that distant metastasis for stage
IIIA endometrial carcinoma with isolated involvement of
the adnexa or serosa should be the primary target. Adding
eﬀective systemic therapy to surgery and adjuvant radio-
therapy might improve the prognosis. Adjuvant systemic
treatment for women with high-risk endometrial carcinoma
as stage IIIA is a controversial clinical topic that is frequently
clouded by strong treatment bias and suboptimal data.
CurrentphaseIIIstudiessuchasthePORTECIII,comparing
postoperative pelvic radiotherapy to radiochemotherapy to
the pelvis followed by adjuvant chemotherapy, might give
some answers in the future.
Several limitations of this study should be noted. Firstly,
it is a retrospective analysis encompassing a 15-year study
period; secondly it is a multicentre study, with the possibility
of patient selection. Indications for adjuvant external radio-
therapy in The Netherlands for FIGO stage IIIA endometrial
carcinoma following TAH + BSO were uniform, but the
indication for vaginal brachytherapy boost diﬀered between
the radiotherapy departments. Despite the relative large
number of patients with stage IIIA in this multi-institutional
study we were not able to do reliable multivariate analysis
in the separate analysis for involvement of adnexa or serosa,
making it diﬃcult to tease out the individual contribution of
prognostic factors.
5.Conclusion
Endometrial carcinoma stage IIIA with isolated involvement
of the adnexa or serosa only has a comparable disease-
speciﬁc survival of 71.8% and 75.4% at 7 years. Locoregional
control for patients with adnexal involvement is excellent
with only 2.2% recurrences, but worse for patients with
serosal involvement at 14.3%. Prognostic factors for DMFS,
DFS, and DSS with only adnexal involvement showed to be
LVSI, grade of diﬀerentiation, and myometrium inﬁltration.
Despite the relative large number of patients with serosal
involvement, no prognostic factors could be found. Due to
the small number, diﬀerences found were not signiﬁcant.
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